As BioMarin Stumbles, Sanofi Gets Breakthrough Status For Hemlibra Challenger

US Filing Expected Shortly

 
• By Andrew McConaghie
Sanofi_Berlin
Sanofi has made rare blood disorders one of its targeted key growth drivers. • Source: Shutterstock

More from Business

More from Scrip